You are viewing: Rest Of Asia Pacific Artificial Intelligence in Drug Discovery Market analysis

The Rest Of Asia Pacific Artificial Intelligence in Drug Discovery Market was valued at $69.4 Million in 2024 and projected to reach to $235.6 Million by 2029, representing a compound annual growth rate of 27.7%. Rest Of Asia Pacific's AI in drug discovery market is poised for exceptional growth through 2029, driven by increasing digitalization of pharmaceutical R&D operations and rising investments in biotech infrastructure.

Rest Of Asia Pacific Artificial Intelligence in Drug Discovery Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Rest Of Asia Pacific Artificial Intelligence in Drug Discovery Market Trends and Insights

  • Rest Of Asia Pacific represents a critical growth region as pharmaceutical and biotech companies increasingly adopt AI-driven solutions to accelerate drug development timelines and reduce research costs.
  • The region's emerging economies, coupled with growing investments in healthcare infrastructure and R&D capabilities, are positioning Rest Of Asia Pacific as a key hub for AI-enabled drug discovery innovation. Rest Of Asia Pacific's market growth is driven by rising collaboration between local research institutions and global pharmaceutical firms, alongside government initiatives supporting digital health transformation.
  • The 27.7% compound annual growth rate reflects Rest Of Asia Pacific's strong momentum in adopting machine learning, deep learning, and predictive analytics for target identification, lead optimization, and clinical trial design.
  • By 2029, Rest Of Asia Pacific is expected to capture significant market share as regulatory frameworks mature and cost-effective AI solutions become more accessible to regional stakeholders..

Key Market Statistics

  • CAGR (2024-2029) 27.7% CAGR
  • Market Size, 2024 ~USD 69.4 Million
  • Forecast, 2029 ~USD 235.6 Million
  • Country Rest Of Asia Pacific

Rest Of Asia Pacific Artificial Intelligence in Drug Discovery Market Overview

Rapid Market Expansion :

Rest Of Asia Pacific's AI in drug discovery market is growing at 27.7% CAGR, driven by increasing adoption of AI-powered solutions among pharmaceutical and biotech companies seeking to accelerate development timelines and reduce research costs.

Significant Growth Trajectory :

Market valuation is projected to surge from $69.4 million in 2024 to $235.6 million by 2029, representing a 239% increase over five years and positioning the region as a high-potential investment destination.

Regional Investment Momentum :

Rest Of Asia Pacific is emerging as a critical growth hub as local pharmaceutical companies and emerging biotech startups increasingly leverage AI technologies to enhance drug discovery efficiency and competitive positioning.

Cost Optimization Driver :

AI adoption in the region is primarily motivated by the need to reduce R&D expenditures and accelerate time-to-market, making it an attractive solution for cost-conscious pharmaceutical organizations across Rest Of Asia Pacific.

Rest Of Asia Pacific Artificial Intelligence in Drug Discovery Market Dynamics

  • The region's growing pool of skilled data scientists and AI researchers, combined with government initiatives supporting healthcare innovation, creates a favorable ecosystem for AI adoption.
  • Pharmaceutical companies are increasingly establishing AI research centers and partnering with local tech firms to leverage regional expertise and cost advantages. The market outlook remains highly positive as Rest Of Asia Pacific countries strengthen regulatory frameworks for AI-driven drug development and increase funding for healthcare technology initiatives.
  • Emerging markets within the region are expected to become significant contributors to global drug discovery pipelines, with AI serving as a critical enabler.
  • Strategic collaborations between multinational pharmaceutical companies and regional players will further accelerate market penetration and innovation adoption across Rest Of Asia Pacific..

Market Ecosystem

logo-mobile

AI IN DRUG DISCOVERY MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
GPU-accelerated computing, BioNeMo foundation models, generative AI, molecular simulation, and high-performance computing platforms supporting target discovery, protein engineering, molecular design, and virtual screening Faster AI model training | Accelerated molecular discovery | Reduced computational time | Scalable drug discovery workflows | Improved research productivity
Physics-based molecular modeling, computational chemistry, AI-assisted drug design, virtual screening, and lead optimization through an integrated computational drug discovery platform Higher prediction accuracy | Improved lead optimization | Lower experimental costs | Accelerated candidate selection | Increased probability of clinical success
Generative AI-powered target identification, de novo molecule generation, biomarker discovery, and end-to-end drug discovery through the Pharma.AI platform integrating biology, chemistry, and clinical data Shortened discovery timelines | Rapid identification of novel drug candidates | Improved target validation | Enhanced R&D efficiency | Reduced drug development costs
AI-driven phenomics platform combining high-content cellular imaging, machine learning, automated experimentation, and large-scale biological datasets for target discovery and therapeutic development Faster target identification | Improved biological insights | Higher-quality candidate selection | Increased experimental throughput | Enhanced translational research efficiency
AI foundation models, protein structure prediction, cloud-based AI infrastructure, and multimodal data analytics supporting drug target discovery, molecular modeling, and biomedical research Improved biological understanding | Accelerated target discovery | Scalable AI infrastructure | Enhanced predictive modelling | Faster scientific innovation

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Drug Delivery Devices

Top Technologies
  • Disposable Autoinjectors
  • Reusable Autoinjectors
  • Insulin Pumps
  • Pen Injectors
  • Transdermal Patches
Top Companies
  • Becton, Dickinson and Company
  • Novo nordisk a/s
  • Terumo Corporation
  • Medtronic plc
  • Nipro Corporation

    Healthcare It

    Top Technologies
    • Computed Tomography (CT)
    • Machine Learning
    • Magnetic Resonance Imaging (MRI)
    • Natural Language Processing (NLP)
    • Predictive Analytics
    Top Companies
    • CERNER CORPORATION
    • PHILIPS HEALTHCARE
    • Oracle Corporation
    • GE HealthCare Technologies Inc.
    • Siemens healthineers

      Analytics

      Top Technologies
      • Natural Language Processing (NLP)
      • Machine Learning
      • Supply Chain Management
      • Predictive Analytics
      • Image Sensors
      Top Companies
      • International Business Machines Corporation
      • MICROSOFT CORPORATION
      • Oracle Corporation
      • SAP SE
      • GOOGLE

        Key Takeaways

        • Rest Of Asia Pacific's AI drug discovery market is valued at $69.4 million in 2024 and will grow to $235.6 million by 2029, representing a 27.7% CAGR.
        • Rest Of Asia Pacific is emerging as a strategic hub for AI-driven pharmaceutical R&D due to cost advantages, skilled talent pools, and government support for digital health initiatives.
        • Rest Of Asia Pacific's market expansion is fueled by increased partnerships between regional biotech firms and multinational pharmaceutical companies seeking to leverage AI for faster drug development.
        • Rest Of Asia Pacific's regulatory environment and healthcare infrastructure improvements are enabling wider adoption of AI technologies in drug discovery workflows by 2029.

        Artificial Intelligence in Drug Discovery Market Report Scope

        Report Metric Details
        Base Year 2024
        Fastest Growing Segment ANTIBODY & OTHER BIOLOGICS DESIGN (Type)
        Forecast Period 2024-2029
        Growth Rate CAGR of 29.9% from 2024 to 2029
        Largest Segment PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES (End User)
        Market Size Base Year (Billions) ~USD 1.86 (2024)
        Revenue Forecast (Billions) ~USD 6.89 (2029)
        Segments Covered Process, Use Case, Type, Therapeutic Area, Player Type, Ai Tool, Deployment, End User, Process 2022-2029

        Rest Of Asia Pacific Artificial Intelligence in Drug Discovery Market Report Segmentation

        9 segment dimensions are covered across the global market.

        By Process

        • Candidate Selection & Validation
        • Hit Identification & Prioritization
        • Hit-To-Lead Identification/Lead Generation
        • Lead Optimization
        • Target Identification & Selection
        • Target Validation

        By Use Case

        • De Novo Drug Design
        • Drug Optimization
        • Drug Repurposing
        • Safety & Toxicity
        • Understanding Diseases

        By Type

        • Antibody & Other Biologics Design
        • Antibody & Other Biologics Optimization
        • Deep Learning
        • Other Machine Learning Technologies
        • Reinforcement Learning
        • Small Molecule Design
        • Small Molecule Optimization
        • Small-Molecule Design
        • Small-Molecule Optimization
        • Supervised Learning
        • Unsupervised Learning
        • Vaccines Design
        • Vaccines Optimization

        By Therapeutic Area

        • Cardiovascular Diseases
        • Immunology
        • Infectious Diseases
        • Mental Health Disorders
        • Metabolic Diseases
        • Neurology
        • Oncology
        • Other Therapeutic Areas

        By Player Type

        • AI Technology Providers
        • Business Process Service Providers
        • End-To-End Solution Providers
        • Niche/Point Solution Providers

        By Ai Tool

        • Computer Vision
        • Context-Aware Processing & Computing
        • Image Analysis
        • Machine Learning
        • Natural Language Processing

        By Deployment

        • Cloud-Based Deployment
        • On-Premises Deployment
        • SaaS-Based Deployment

        By End User

        • Contract Research Organizations
        • Pharmaceutical & Biotechnology Companies
        • Research Centers And Academic & Government Institutes

        By Process 2022-2029

        • Candidate Selection & Validation
        • Hit Identification & Prioritization
        • Hit-To-Lead Identification/Lead Generation
        • Lead Optimization
        • Target Identification & Selection
        • Target Validation

        Target Audience

        • Pharmaceutical & Biotech Companies : Rest Of Asia Pacific-based and multinational pharma firms need regional market intelligence to guide R&D investments, AI platform selection, and competitive positioning in this high-growth market.
        • AI & Software Solution Providers : Technology vendors targeting the drug discovery space require detailed Rest Of Asia Pacific market data to identify customer segments, assess market readiness, and develop region-specific product strategies.
        • Investment & Private Equity Firms : Investors evaluating opportunities in Rest Of Asia Pacific's healthcare tech sector need comprehensive market analysis to identify promising startups, assess growth potential, and make informed funding decisions.
        • Government & Regulatory Bodies : Healthcare policymakers and regulatory agencies in Rest Of Asia Pacific require market insights to develop supportive frameworks, allocate R&D funding, and foster innovation ecosystems for AI-driven drug discovery.
        • Research & Consulting Institutions : Academic centers and consulting firms need Rest Of Asia Pacific-specific data to support client advisory services, publish research, and contribute to industry knowledge on regional AI adoption trends.

        Reasons to Buy this Report

        • Regional Market Sizing & Forecasts : Obtain precise valuation data specific to Rest Of Asia Pacific ($69.4M in 2024, $235.6M by 2029) with detailed year-by-year projections to support strategic planning and investment decisions in the region.
        • Competitive Landscape Intelligence : Identify key players, emerging startups, and market consolidation trends unique to Rest Of Asia Pacific to benchmark competitive positioning and identify partnership or acquisition opportunities.
        • Regional Growth Drivers & Barriers : Understand region-specific factors influencing AI adoption, including regulatory environment, talent availability, infrastructure maturity, and government support initiatives affecting market dynamics in Rest Of Asia Pacific.
        • Investment & Expansion Strategy : Leverage Rest Of Asia Pacific-focused insights to identify high-potential markets, optimal entry strategies, and localization requirements for pharmaceutical and AI technology companies expanding in the region.
        • Technology Adoption Trends : Analyze which AI applications (target identification, lead optimization, clinical trial design) are gaining traction in Rest Of Asia Pacific to align product development and go-to-market strategies accordingly.

        Frequently asked questions

        What is the current market size of AI in drug discovery in Rest Of Asia Pacific?

        Rest Of Asia Pacific's AI drug discovery market was valued at $69.4 million in 2024 and is projected to reach $235.6 million by 2029.

        What is the expected growth rate for Rest Of Asia Pacific's AI drug discovery market?

        Rest Of Asia Pacific's AI drug discovery market is expected to grow at a compound annual growth rate (CAGR) of 27.7% from 2024 to 2029.

        What factors are driving growth in Rest Of Asia Pacific's AI drug discovery market?

        Rest Of Asia Pacific's market growth is driven by increasing R&D investments, government digital health initiatives, cost-effective AI solutions, and rising collaborations between regional and global pharmaceutical companies.

        Which countries in Rest Of Asia Pacific are leading AI drug discovery adoption?

        Rest Of Asia Pacific includes emerging markets with growing biotech ecosystems and research capabilities that are increasingly adopting AI technologies for drug discovery applications.

        How does Rest Of Asia Pacific's AI drug discovery market compare to other regions?

        Rest Of Asia Pacific's 27.7% CAGR demonstrates strong regional momentum, positioning it as a high-growth market within the broader Asia Pacific region for AI-enabled pharmaceutical R&D.

        RESEARCH METHODOLOGY

        The study involved significant activities in estimating the current size of the AI in drug discovery market. Exhaustive secondary research was done to collect information on the market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the AI in drug discovery market.

        Secondary Research

        This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and Companies House documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in drug discovery solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.

        Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in drug discovery vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.

        Primary Research

        In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources are mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.

        Primary research was conducted to identify segmentation types; industry trends; key players; and key market dynamics such as drivers, restraints, opportunities, challenges, industry trends, and strategies adopted by key players. After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at.

        In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

        Breakdown of the Primary Respondents:

        AI in Drug Discovery Market Size, and Share

        Note: Other designations include sales managers, marketing managers, and product managers.
        Note: Tiers are defined based on a company’s total revenue as of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

        To know about the assumptions considered for the study, download the pdf brochure

        Market Size Estimation

        The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (revenue share analysis of leading players) and the top-down approach (assessment of utilization/adoption/penetration trends by offering, function, application, deployment, tools, end user, and region).

        AI in Drug Discovery Market : Top-Down and Bottom-Up Approach

        AI in Drug Discovery Market Top Down and Bottom Up Approach

        Data Triangulation

        After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the AI in drug discovery market. 

        Market Definition

        The AI in drug discovery market comprises artificial intelligence-based software platforms and computational solutions that accelerate early-stage drug discovery by enabling target identification, lead optimization, candidate selection, and drug repurposing. These solutions leverage technologies such as machine learning, deep learning, and generative AI to improve R&D efficiency, reduce costs, and shorten drug development timelines.

        Key Stakeholders

        • AI in drug discovery software vendors
        • AI in drug discovery service providers
        • Pharmaceutical companies
        • Biotechnology companies
        • AI technology providers
        • Drug discovery software providers
        • Contract Research Organizations (CROs)
        • Academic and research institutes
        • Clinical research organizations
        • Cloud service and high-performance computing (HPC) providers
        • Genomics and multi-omics data providers
        • Healthcare data and bioinformatics companies
        • Government agencies and regulatory authorities
        • Venture capital firms and strategic investors
        • Healthcare and life sciences consulting firms
        • Contract Development and Manufacturing Organizations (CDMOs)
        • Healthcare providers (involved in translational research)
        • Precision medicine and companion diagnostics companies
        • Life sciences distributors and technology integrators

        Report Objectives

        • To describe and forecast the global AI in drug discovery market, by process, use case, therapeutic area, player type, AI tool, deployment model, end user, and region, in terms of value
        • To provide detailed information regarding the factors such as the drivers, restraints, opportunities, and challenges influencing the growth of the market
        • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall AI in drug discovery market
        • To analyze market opportunities for stakeholders and provide details of the competitive landscape for market leaders
        • To forecast the size of the AI in drug discovery market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa, in terms of value
        • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies in the market
        • To track and analyze competitive developments such as product & service launches, expansions, partnerships, agreements, collaborations, and acquisitions in the AI in drug discovery market
        • To benchmark players within the AI in drug discovery market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offering

        Available customizations:

        With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

        Geographic Analysis

        • Further breakdown of the Rest of Europe’s AI in drug discovery market into Denmark, Norway, and others

        • Further breakdown of the Rest of Asia Pacific AI in drug discovery market into Vietnam, New Zealand, Australia, South Korea, and others

        Company Information

        • Detailed analysis and profiling of additional market players (up to 5)

         

        Get the Full Artificial Intelligence in Drug Discovery Market Report

        Full forecast, segment splits, and company analysis for all Artificial Intelligence in Drug Discovery Market.

        Need a Tailored Report?

        Customize this report to your needs

        Get 10% FREE Customization

        Customize This Report
        Fact checked
        DMCA.com Protection Status